China’s Brii Bio invests $100M more for SARS-CoV-2 mAb combination therapy

Brii Biosciences is committing an additional $100 million to advance global regulatory filings and commercial efforts for its investigational SARS-CoV-2 monoclonal antibody (mAb) combination therapy, BRII-196/BRII-198. Following on the heels of a positive Phase III data readout from the ACTIV-2 trial, and as countries around the world continue to face a significant resurgence of COVID-19 cases, the company is doubling down on its efforts to bring BRII-196/BRII-198 to a broad range of patients as a promising potential new treatment option for COVID-19. BRII-196/BRII-198 is a SARS-CoV-2 neutralising monoclonal antibody combination therapy. Interim results from Phase III of the NIH-sponsored ACTIV-2 trial recently demonstrated that the combination therapy achieved a statistically significant reduction, 78 per cent, of relative risk in the combined endpoint of hospitalisation and death in non-hospitalised COVID-19 patients at high risk of clinical progression.